ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones Portfolio News / By Karina Tin ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones Read More »
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones Portfolio News / By Karina Tin Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones Read More »
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations Portfolio News / By Karina Tin ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations Read More »
A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of its Precision Cell Therapies Using its Proprietary Tmod(TM) Technology Platform Portfolio News / By Karina Tin A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of its Precision Cell Therapies Using its Proprietary Tmod(TM) Technology Platform Read More »
Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics Portfolio News / By Karina Tin Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics Read More »
RAPT Therapeutics Announces $150 Million Private Placement Portfolio News / By Karina Tin RAPT Therapeutics Announces $150 Million Private Placement Read More »
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-acting Anti-ige Antibody Portfolio News / By Karina Tin RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-acting Anti-ige Antibody Read More »
NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate Portfolio News / By Karina Tin NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate Read More »
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Portfolio News / By Karina Tin Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Read More »
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition Portfolio News / By Karina Tin Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition Read More »
